April 29th 2025
IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.
April 28th 2025
The company’s branded form of nadofaragene firadenovec-vncg will also be produced at a hub in Parsippany, NJ.
April 24th 2025
The deal for the San Diego hub provides the CDMO with its first-ever North American manufacturing location for prefilled syringes and cartridges.
April 15th 2025
One expert's take on reshoring pharma manufacturing services in the US amid likely tariffs to drugs looming.
A panel discussion uncovers ways to deliver personalized therapy ops in a timely fashion.
2018 report on US biotech hiring shows surprising softness
Data are down for 2016-7, but still relatively high compared to prior years; UPDATED
FDA hammers IQVIA over opioid-consumption data quality
Questions raised over how prescription dosages translate into bulk consumption; IQVIA ‘stand(s) behind our data methodologies’
Trump’s drug-pricing speech is long on rhetoric, short on substantive action
Eagerly anticipated address avoids major policy changes while chipping away at well-recognized pricing disincentives
Alternative payment models for new cellular and genetic therapies
With new cellular and genetic therapies, the reimbursement process will need to evolve
340B program represents 6% or more of US pharma market
Purchases totaled $19.3 billion, up 19% over 2016, say Drug Channels' Adam Fein
Mark Merritt will leave PCMA leadership at year-end
Move comes as drug pricing policies get heightened attention in Washington
Asembia expands its hub services offerings
Company celebrates its growth at annual industry event
Nominal drug spending hit $452.6 billion in the US in 2017, says IQVIA
While nominal spending was up 1.4%, actual net spending was only 0.6% greater than 2016
The contract research market: revenues are growing while vendors are consolidating
Projected growth rates for outsourced work range from 12 to 17%
Allogene Therapeutics, a new biotech, launches with an alternative CAR-T technology
So-called ‘off the shelf’ CAR-T treatments could change the field just as first products enter commercialization
Getting at the value of value-based drug pricing models
Existing ‘pay for performance’ models do not scale up well yet
Global drug spending was $1.135 trillion in 2017, says IQVIA
Forecast is for 3-6% CAGR through 2022
Is the proposed Cigna-Express Scripts deal the end of the PBM era?
$67-billion Cigna bid, if permitted, would pull in the last large independent PBM
PBMs earn more than other actors in the pharma supply chain
Financial analysis shows PBMs’ greater conversion of profits to earnings
Private equity builds a commercialization services powerhouse
Dohmen Life Sciences Services is joined to a trio of recent acquisitions
Supermarket operator Albertsons will acquire remaining Rite Aid stores
Rite Aid brand will be expanded to include Albertsons’ pharmacies
Walgreens is in ‘early stage’ talks to acquire AmerisourceBergen
Merger of two giants in their respective fields has global implications
Model N proposes revenue management as a platform for ‘digital reinvention’
New software solutions and an updated Revenue Cloud for Pharma
White House Council builds a case for pharma pricing reform
Most proposed solutions are already in the works
Amazon, Berkshire Hathaway and JP Morgan Chase will partner on employee healthcare
Another attempt by payers to control their healthcare costs; possible broader implications
Celgene acquires Juno Therapeutics for $9 billion
Deal brings Celgene into the CAR-T arena
Sanofi will acquire Bioverativ for $11.6 billion
Acquired company lasted less than a year after Biogen spinoff
HDA members handled 95.7% of US pharmaceutical distribution in 2016
HDA 2017-8 Factbook details rising wholesaler involvement
CVS Health will acquire Aetna in a mammoth $69-billion deal
Acquisition brings retail pharmacy and PBM together with a health insurer
Express Scripts unloads the rest of United BioSource
Private equity firm acquires UBC
EMA’s new home: Amsterdam
The Netherlands wins out in the competition to move the agency from London
More consolidation in drug wholesaling: AmerisourceBergen to buy H. D. Smith
$815-million deal to close in early 2018
Managing pharma auto fleets
A conversation with Jim Cleary, AmerisourceBergen
If CVS Health-Aetna doesn’t happen, something else will
Rumors of a $60-billion acquisition shake up healthcare services landscape—and what about Amazon?